Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.

Details

Serval ID
serval:BIB_D73B0A8508A7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.
Journal
Experimental Parasitology
Author(s)
Utaile M., Kassahun A., Abebe T., Hailu A.
ISSN
1090-2449 (Electronic)
ISSN-L
0014-4894
Publication state
Published
Issued date
2013
Volume
134
Number
1
Pages
68-75
Language
english
Abstract
Cutaneous Leishmaniasis (CL) caused by Leishmania aethiopica is a public health and social problem with a sequel of severe and mutilating skin lesions. It is manifested in three forms: localized CL (LCL), mucosal CL (MCL) and diffuse CL (DCL). Unresponsiveness to sodium stibogluconate (Sb(V)) is common in Ethiopian CL patients. Using the amastigote-macrophage in vitro model the susceptibility of 24 clinical isolates of L. aethiopica derived from untreated patients was investigated. Eight strains of LCL, 9 of MCL, and 7 of DCL patients together with a reference strain (MHOM/ET/82/117/82) were tested against four antileishmanial drugs: amphotericin B, miltefosine, Sb(V) and paromomycin. In the same order of drugs, IC(50) (μg/ml±SD) values for the 24 strains tested were 0.16±0.18, 5.88±4.79, 10.23±8.12, and 13.63±18.74. The susceptibility threshold of isolates originating from the 3 categories of patients to all 4 drugs was not different (p>0.05). Maximal efficacy was superior for miltefosine across all the strains. Further susceptibility test could validate miltefosine as a potential alternative drug in cases of sodium stibogluconate treatment failure in CL patients.
Keywords
Amphotericin B/pharmacology, Animals, Antimony Sodium Gluconate/pharmacology, Antiprotozoal Agents/pharmacology, Cells, Cultured, Ethiopia, Humans, Inhibitory Concentration 50, Leishmania/classification, Leishmania/drug effects, Leishmaniasis, Cutaneous/drug therapy, Leishmaniasis, Cutaneous/parasitology, Macrophages, Peritoneal/parasitology, Mice, Parasitic Sensitivity Tests/methods, Paromomycin/pharmacology, Phosphorylcholine/analogs & derivatives, Phosphorylcholine/pharmacology
Pubmed
Web of science
Create date
23/05/2013 9:30
Last modification date
20/08/2019 15:57
Usage data